Skip to main content
. Author manuscript; available in PMC: 2018 Jul 10.
Published in final edited form as: Cancer Cell. 2017 Jun 29;32(1):88–100.e6. doi: 10.1016/j.ccell.2017.05.011

Figure 4. ILF2 Is Required for the RNA Splicing of Genes Involved in DNA Repair.

Figure 4

(A) Silver stained gel of proteins isolated from untreated or melphalan-treated JJN3 cells (input) and immunoprecipitated with anti-IgG or anti-ILF2 antibodies. Blue bands denote fractions that were excised and analyzed by mass spectrometry analysis (upper panel). Western blot analysis of the indicated proteins in the lysate isolated from JJN3 cells (input) and immunoprecipitated with anti-IgG or anti-ILF2 antibodies (bottom panel).

(B) Significantly enriched pathways relative to the 1750 events of aberrant splicing in ILF2 shRNA–transduced JJN3 cells as compared to non-silencing shRNA–transduced JJN3 cells. ILF2 shRNA #2 was used for this experiment, which was performed in duplicate.

(C) Significantly enriched pathways relative to the 3652 events of aberrant splicing in melphalan-treated, non-silencing shRNA–transduced JJN3 cells as compared to untreated, non-silencing shRNA–transduced JJN3 cells. The experiment was performed in duplicate.

(D) Significantly enriched pathways relative to the 3357 events of aberrant splicing in melphalan-treated, ILF2 shRNA–transduced JJN3 cells as compared to melphalan-treated, non-silencing shRNA–transduced JJN3 cells. ILF2 shRNA #2 was used for this experiment, which was performed in duplicate.

See also Figure S4 and Tables S2, S3 and S4.

HHS Vulnerability Disclosure